sepsis-induced cardiomyopathy
Conditions
Interventions
Control Group:To give conventional Western medicine treatment, treatment for 5 days
Experimental Group:On the basis of conventional Western medicine treatment, to give the core prescription (including: Huangqi 60g, Danshen 30g, Shu Fuzi 10g (decocting first), Danggui 10g, Chuanxiong
The above decoction was uniformly decocted by Kangmei Pharmaceutical, decocted to 100ml, one dose per day, oral/nasal feeding), and treated for 5 days
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Patients who meet the diagnostic criteria of TCM and Western medicine for septic cardiomyopathy and whose TCM syndrome is Qi deficiency induced blood stasis and fire toxin pattern; (2) Those with complete clinical information and diagnostic data of hospitalisation; (3) 18 years old = age < 85 years old, regardless of gender; (4) Voluntary participation in this study and informed consent signed by patients or authorized family members.
Exclusion criteria
Exclusion criteria: (1) Patients with acute myocardial infarction; Patients with cardiomyopathy; Patients with stress cardiomyopathy; Severe heart failure (NYHA grade IV, or EF=30%); (2) Patients with allergies or allergies to core prescription ingredients; (3) Uncontrolled gastrointestinal bleeding, intestinal obstruction, gastrointestinal intolerance and other patients requiring fasting or unable to enteral nutrition; Patients with severe immune diseases or malignant tumors; Patients with serious diseases such as mental disorders, hematopoietic system diseases, malignant tumors, severe liver and kidney insufficiency, and severe immune deficiency; (4) Patients who are unable to cooperate with the study and those who are expected to die within 24 hours of admission to the ICU; (5) Women who are pregnant or planning to become pregnant, breastfeeding women; (6) Have participated or are participating in other clinical investigators within the last three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N terminal pro B type natriuretic peptide, NT-proBNP;Hypersensitive C-reactive protein, hs-CRP;White blood cell, WBC;Neutrophilcount, NEUT;Lactic acid, Lac;Interleukin 6, IL-6;Creatine Kinase, CK;Creatine kinase isoenzymes, CK-MB;Lactate dehydrogenase, LDH;Mean arterial, MAP;Total volume urine;APACHE II;Sequential Organ Failure Assessment, SOFA;28 day mortality;Brain natriuretic peptide, BNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiogram;Troponin T,TnT;Procaicitonin, PCT;Tumor Necrosis Factor-a,TNF-a; | — |
Countries
China
Contacts
Public ContactShuai Mao
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed